Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.34 |
| ▸ | WDR5 | P61964 | 4/20 | 0.33 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24214281 | 0.83 | OPRM1 (0.40) | OPRM1WDR5 | |
| SCHEMBL19212422 | 0.82 | MAOB (0.39) | OPRM1 | |
| SCHEMBL10242347 | 0.81 | OPRM1 (0.38) | OPRM1WDR5 | |
| SCHEMBL8017729 | 0.81 | OPRM1 (0.51) | OPRM1 | |
| SCHEMBL2300 | 0.79 | OPRM1 (0.46) | OPRM1WDR5 | |
| SCHEMBL27361970 | 0.79 | KMT2A (0.35) | OPRM1WDR5 | |
| SCHEMBL29841501 | 0.79 | KMT2A (0.35) | OPRM1WDR5 | |
| SCHEMBL17316802 | 0.78 | OPRM1 (0.32) | OPRM1 | |
| SCHEMBL29820517 | 0.78 | P2RX7 (0.34) | MBOAT4 | |
| SCHEMBL24666234 | 0.78 | P2RX7 (0.34) | MBOAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4261211-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2023-10-18 | — | — | EP | disclosed |
| WO-2022122037-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | 上海奕拓医药科技有限责任公司 | 2022-06-16 | — | — | WO | disclosed |
| CN-106414429-B | Pyrazole compounds and their use as T-type calcium channel blockers | 爱杜西亚药品有限公司 | 2020-01-03 | — | — | CN | disclosed |
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-09-04 | — | — | US | disclosed |
| US-20180105496-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-19 | — | — | US | disclosed |
| US-9932314-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-03 | — | — | US | disclosed |
| EP-3152199-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | Actelion Pharmaceuticals Ltd. (CH) | 2017-04-12 | — | — | EP | disclosed |
| US-20170096399-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-04-06 | — | — | US | disclosed |
| WO-2015186056-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-10 | — | — | WO | disclosed |
| EP-2609092-B1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2015-04-01 | — | — | EP | disclosed |
| EP-2609092-B1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2015-04-01 | — | — | EP | disclosed |
| US-8580829-B2 | Oxadiazole inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-8580829-B2 | Oxadiazole inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-8580829-B2 | Oxadiazole inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| EP-2609092-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | Boehringer Ingelheim International GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-20120214787-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120214787-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120214787-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| WO-2012027322-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | CACNA1E, CACNA1I, CACNA1G | OPRM1 715/4885WDR5 2312/4885MBOAT4 4812/4885 |
| US-20120214787-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTC4S, LTB4R2 | OPRM1 1988/4885WDR5 2214/4885MBOAT4 2884/4885 |
| US-20170096399-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1I, CACNA1G | OPRM1 715/4885WDR5 2312/4885MBOAT4 4812/4885 |
| US-20180105496-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1I, CACNA1G | OPRM1 715/4885WDR5 2312/4885MBOAT4 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.